Currently, several therapeutic antibodies against GARP are under evaluation in clinical trials (e.g. phase 1: NCT04419532, NCT05606380, NCT05821595, NCT05869240 in unspecific advanced solid tumours or lymphoma and phase 2/3: NCT06236438 in untreated metastatic non-squamous non-small cell lung cancer (NSCLC)) [25,60,61]. This evidence concerns the gene LRRC32 and lymphoma.